Docoh
Loading...

JAN JanOne

JanOne, Inc. focuses on developing treatments for diseases that cause severe pain and markets drugs with non-addictive pain-relieving properties. It operates through the following segments: Biotechnology, Recycling and Technology. The Recycling segment is a turnkey appliance recycling program. The Biotechnology segment deals in the development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The Technology segment develops technology to enable low cost, location-based products and services. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Company profile

Ticker
JAN
Exchange
CEO
Tony Isaac
Employees
Incorporated
Location
Fiscal year end
Former names
APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
SEC CIK
IRS number
411454591

JAN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
18 Apr 21
2 Jan 22
Quarter (USD)
Jan 21 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from JanOne earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 379K 379K 379K 379K 379K 379K
Cash burn (monthly) 86.33K 8.5K 980.67K 802.5K (positive/no burn) 51.42K
Cash used (since last report) 306.9K 30.22K 3.49M 2.85M n/a 182.78K
Cash remaining 72.1K 348.78K -3.11M -2.47M n/a 196.22K
Runway (months of cash) 0.8 41.0 -3.2 -3.1 n/a 3.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Feb 21 Virland A Johnson Common Stock Sell Dispose S No No 8.65 4,112 35.57K 32,933
3 Nov 20 Virland A Johnson Common Stock Sell Dispose S No No 3.61 1,469 5.3K 37,045
31 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.19 4,900 10.73K 38,514
27 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.21 1,900 4.2K 43,414
25 Mar 20 Virland A Johnson Common Shares Sell Dispose S No No 2.19 6,686 14.64K 45,314

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 7 0 NEW
Opened positions 6 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 45K 0 NEW
Total shares 9.24K 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
UBS UBS Group AG - Registered Shares 5.36K $26K NEW
Tower Research Capital 3.69K $18K NEW
BLK Blackrock 173 $1K NEW
WFC Wells Fargo & Co. 8 $0 NEW
BAC Bank Of America 4 $0 NEW
MS Morgan Stanley 1 $0 NEW
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
UBS UBS Group AG - Registered Shares 5.36K +5.36K NEW
Tower Research Capital 3.69K +3.69K NEW
BLK Blackrock 173 +173 NEW
WFC Wells Fargo & Co. 8 +8 NEW
BAC Bank Of America 4 +4 NEW
MS Morgan Stanley 1 +1 NEW
Proequities 0 0

Financial report summary

?
Competition
LBS
Risks
  • If we fail to implement our biopharmaceutical business strategy or if our biopharmaceutical business strategy is ineffective, our financial performance could be materially and adversely affected.
  • We have identified and disclosed in this Form 10-K material weaknesses in our internal control over financial reporting. If we are not able to remediate these material weaknesses and maintain an effective system of internal controls, we may not be able to accurately or timely report our financial results, which could cause our stock price to fall or result in our stock being delisted.
  • Our business model is entirely dependent on certain patent rights licensed to us from the Licensors (as defined below), and the loss of those license rights would, in all likelihood, cause our business, as presently contemplated, to fail.
  • Even if we receive regulatory approval for our product candidate, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.
  • Even if we obtain marketing approval for our product candidate, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidate could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidate.
  • Obtaining and maintaining regulatory approval of our product candidate in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidate in other jurisdictions.
  • Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Third-party coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.
  • It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.
  • It is difficult and costly to block others from developing similar products for other indications, and we cannot ensure that these products will not be less expensive and thus be prescribed off-label by physicians for use in our indications.
  • Our product candidate may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
  • Our revenues, earnings and cash flows will fluctuate based on changes in commodity prices.
  • We purchase our replacement appliances from third-party manufacturers, who we believe manufacture those appliances in China and Mexico, and, as a result, international trade conditions could adversely affect us.
  • If our third-party collection or delivery services are unable to meet our promised pickup and delivery schedules, our net sales may decline due to a decline in customer satisfaction.
  • Our sales may not be an indication of our future results of operations because they fluctuate significantly.
  • Significant shortages in diesel fuel supply or increases in diesel fuel prices will increase our operating expenses.
  • Our revenues from recycling contracts are subject to seasonal fluctuations and are dependent on the utilities’ advertising and promotional activities for contracts in which we do not provide advertising services.
  • GeoTraq has incurred significant operating losses since inception and expects the losses will continue into the future. If the losses continue GeoTraq may have to suspend operations or cease operations.
  • GeoTraq does not have sufficient funds to complete each phase of its proposed plan of operation and as a result may have to suspend operations.
  • GeoTraq outsources the research and development of its technology, and as a result it is dependent upon those third-party developers to develop our products in a timely and cost-efficient manner while maintaining a minimum level of quality.
  • Cellular service providers on which GeoTraq’s technology is dependent may change the terms by which the technology is used on their networks, which could result in lower revenue and adverse effects on our business.
  • GeoTraq’s ability to increase or maintain its customer base and revenue will be impaired if cellular service providers do not allow GeoTraq Technology access to their networks.
  • Isaac Capital Group, LLC (“ICG”) owns a large percentage of our voting stock, which may allow them to control substantially all matters requiring stockholder approval.
Management Discussion
  • Revenue remained relatively constant for the fiscal year ended January 2, 2021 as compared to the fiscal year ended December 28, 2019. Replacement Appliance revenue increased $1,953 or 14.3% due to higher volumes from two customers, offset by a decrease in Recycling and Byproducts revenue of $3,183 or 14.8% due to the temporary closure of our facilities as a result of COVID-19 and decreased volumes from our customers.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abbott, abbreviated, ABIPP, abnormal, absent, absorbed, ACA, accessible, ACE, acid, addiction, adrenal, adult, advice, Aid, AJP, Akron, al, Alabama, Alan, Allen, allergic, alleviate, Altium, Alzheimer, Amol, amputation, anatomical, ancillary, ANDA, anesthesia, anesthesiology, angiogram, angioplasty, Angiotensin, anticoagulant, antidote, antiplatelet, apportioned, arena, arrest, Arya, ASIPP, aspirin, asymptomatic, attenuating, AU, backlog, bar, baseline, Bed, bile, bioactivity, bioequivalence, bioequivalent, Biol, biologic, biological, biologically, biosimilar, Bir, Birmingham, bleeding, blockage, bloodstream, blue, blush, bone, boxed, BPI, brain, break, breakthrough, Brendan, bridging, Brigham, brochure, Brown, BS, burdensome, bypassed, cabinet, Cadillac, calf, cancer, carboxy, cardiac, Cardiology, cardiovascular, cartilage, casting, Castle, cat, CDC, cessation, children, Cilostazol, Circ, circulating, Cleveland, CLI, clopidogrel, closure, clotting, codified, cohort, Comp, comparison, compound, concretely, Concurrent, Congressional, Connolly, constant, constipation, Cooke, cord, correlated, corticosteroid, Coulston, COVID, Cowen, cPTIO, customary, cutting, cytoprotection, DABA, DABIPP, DABPM, DAPI, Dartmouth, Dean, death, DeBakey, Decentralized, deducting, deep, dehiscence, density, diabetic, diameter, diet, Dilation, Diplomate, disability, disbursement, discharge, dispensing, dispersed, dissemination, distal, distance, DM, Doctorate, doppler, dossier, DPN, durability, dysfunction, earnout, East, Edgar, edge, editor, EEA, elapsed, elevated, emotional, Endogenously, endpoint, England, essential, ethnic, EU, Europe, excise, exciting, excretion, expedite, expenditure, explain, explore, fat, fatigue, fault, FDASIA, fellow, fellowship, femoral, fibromyalgia, field, Fillmore, FL, flowmetry, fluid, FMD, forfeited, forgivable, forgiven, founder, Francisco, Frisbee, fulminant, gastrointestinal, gathered, GCP, genetic, Giordano, GLP, glucose, glutathione, glycolation, Governor, greatest, guide, Harmonization, Harvard, heart, heightened, heterogeneity, highlight, highlighting, hind, HIPAA, HMS, hospital, Houston, hundred, hydrogen, hyperglycemia, hypersensitivity, hypertension, hypothesized, IA, IBR, ICG, ICH, IEC, IIb, illustrate, image, immune, impeding, impossible, IMT, inactive, indemnification, inert, infected, infection, inflammation, inflammatory, influenza, injured, inside, instance, insulin, Interbank, interventional, intimal, intolerance, intussusceptive, inversely, ion, Ionic, irreversible, ischemia, ix, JC, Kasich, Kaye, Keith, Kettering, KGaA, kidney, KLC, Kleinbongard, Kumar, Lane, laser, lifestyle, lifted, ligation, limb, literature, LP, lt, Lubbock, lung, MA, main, male, marked, MAs, mask, massage, maximize, Mayo, MBA, McGeorge, McGill, MD, meaningful, medial, medicinal, medicine, Mentzer, Merck, metabolic, metabolism, Metabolite, Methodist, Mexico, mg, mice, microcirculation, microcirculatory, microvascular, migration, mild, mission, misuse, moderate, moiety, molecule, monoclonal, monograph, morbidity, mortality, mounted, multiple, multisystem, muscle, MVD, myocardial, nausea, NCI, necessity, nephropathy, nerve, neurobiology, neurodegenerative, neuropathic, neuropathy, NGF, NIA, NIH, nil, nitrate, nitric, nitrosothiol, nonaddictive, nondeductible, Nonpeptide, Northeastern, nose, NPSI, nuclear, objective, oldest, opportunistically, orphan, overdose, overlap, oversee, oxidation, oxidative, oxide, oxidized, Pacific, pandemic, panel, paradigm, passed, passing, Patel, pathophysiological, pathophysiology, pattern, Paycheck, payor, Payroll, PBS, pediatric, perfused, Perioperative, persistent, pertaining, pervasive, Pfizer, pharmacoeconomic, pharmacology, Pharmacopeia, PhD, Physiol, pill, pipeline, pivotal, placebo, placement, plasma, play, porcine, potent, PPP, PREA, preliminarily, Premarket, profile, Prominent, prompted, promptly, pronounced, propensity, protein, provocation, prudently, PTIO, pulmonary, pulse, PulseOx, pursuit, quadrupled, questionnaire, racial, Radic, Radical, Rakesh, RAND, randomized, ranking, rarefaction, rarity, Rat, reaction, reactivity, red, redox, Regeneration, regimen, rehabilitation, relieved, renegotiate, renegotiation, replicating, reservoir, resistance, respiratory, rest, resting, restitution, retention, retinopathy, reveal, revealed, rheumatologist, RNA, robust, rolling, roughly, row, safer, saliva, sample, sampling, SBA, scientist, score, seemingly, send, sensation, sensory, sequential, session, sharply, shelf, Shield, shortened, shutdown, simplification, sit, situation, Skeletal, skin, smoking, society, soft, Soin, spearhead, spell, spinal, SPY, SRnitrite, staining, statewide, Stepp, steroid, stethoscope, Steven, stimulate, stimulator, stimuli, stretch, stretched, strive, stroke, sublicense, subpopulation, suffice, suggest, suggesting, sulfide, Sunshine, superior, surgery, surgical, surrogate, suspected, swim, symptom, syndrome, synthase, teaching, Tech, temporal, Tennessee, text, textual, therapy, threatening, timeline, toe, tone, top, topline, toxicity, traceability, transform, transiently, trauma, trend, TRICARE, TriState, Tulane, undergo, undergoing, undergraduate, unhealed, Unilateral, Union, unrecognized, upfront, USA, USP, utiizing, VA, vaccine, variant, vascular, vasculature, vasodilatation, vasodilation, vasodilator, vasodilatory, Velocity, version, vessel, viewed, viral, visceral, vitro, vivo, vomiting, waiting, walk, walking, weak, West, whatsoever, whooshing, Windmill, Women, workforce, wrote, xi, xii, xiii, xiv, xv, xvi
Removed: AAP, abruptly, accomplished, activate, adapt, affordable, aggressively, agree, Atlanta, atmosphere, attach, Avenue, bidding, blank, boost, broader, catastrophic, ceased, collateralized, committed, compatibility, compromise, concentrated, concept, conflicting, Consumption, content, continuously, controlling, conversation, core, curtail, custom, cyber, cybersecurity, de, declaring, defending, deflation, Del, deliver, depressed, Diego, dilution, disadvantage, disaster, discretionary, diversion, dual, EEI, embrace, emerge, emerging, emission, enforced, enforcement, engineering, enhanced, enterprise, envisioned, espionage, evidenced, evolving, existence, exit, expansion, experienced, expiring, fashion, fifteen, functionality, Gamble, Gasoline, geopolitical, Georgetown, heavily, housing, hungry, idea, inadvertent, incident, inclusive, indemnified, indemnify, indemnifying, inflation, influence, injunction, instituted, interested, interruption, introduce, Jackson, leasehold, length, locator, macroeconomic, Mar, Maryland, Matula, maturing, McDonough, merchant, merit, Miami, midcap, misappropriation, modified, Montgomery, morale, motivate, networking, NRS, occupancy, offsetting, offshore, online, open, opt, opted, orderly, outflow, overly, owing, PA, pace, parent, Paul, payoff, perception, personal, Philadelphia, philanthropic, pledge, Portability, prevailing, preventative, Procter, proxy, punitive, quantity, quicker, quickly, rebrand, recapture, recession, reclassified, refrain, region, regionally, relate, repairing, replacing, repurchase, rescind, rescinded, residing, Responding, restriction, retrospective, revolver, RPC, ruling, safeguard, seller, sensitive, sentence, sentiment, seq, sized, skilled, slowdown, spend, stand, stronger, subcontracted, successor, supplementary, switch, technically, terrorism, theft, thirty, titled, train, transact, Trust, unamortized, unauthorized, unsalable, upgrading, uphold, venture, volatility, vulnerable, wage, waived, war, Ward, Whirlpool, withhold, worth